Immunohistochemical detection of mutations in the epidermal growth factor receptor gene in lung adenocarcinomas using mutation-specific antibodies

Diagnostic Pathology

Volumn 8, Issue 1, 2013, Pages

  Xiong, Yan ^a   Bai, Yun ^a   Leong, Nufatt ^b   Laughlin, Todd S ^b   Rothberg, Paul G ^b   Xu, Haodong ^b   Nong, Lin ^a   Zhao, Jing ^a   Dong, Ying ^a   Li, Ting ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Epidermal growth factor receptor; Immunohistochemistry; Lung adenocarcinoma; Mutation

Indexed keywords

ANTIBODY; BUFFER; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADENOCARCINOMA; ANTIBODY SPECIFICITY; CHINA; DIAGNOSTIC USE; EXON; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LABORATORY DIAGNOSIS; LUNG TUMOR; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PH; PREDICTIVE VALUE; PROCEDURES; PROSPECTIVE STUDY; REPRODUCIBILITY; RETROSPECTIVE STUDY;

ADENOCARCINOMA; ANTIBODIES; ANTIBODY SPECIFICITY; BUFFERS; CHINA; DNA MUTATIONAL ANALYSIS; EXONS; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MUTATION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SPECIMEN HANDLING;

EID: 84873938814     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-8-27     Document Type: Article

References (19)

1. Tanaka T, Matsuoka M, Sutani A, Gemma A, Maemondo M, Inoue A, Okinaga S, Nagashima M, Oizumi S, Uematsu K. Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer 2010, 126(3):651-655. 10.1002/ijc.24746, 19609951.
2. Cheng L, Alexander RE, Maclennan GT, Cummings OW, Montironi R, Lopez-Beltran A, Cramer HM, Davidson DD, Zhang S. Molecular pathology of lung cancer: key to personalized medicine. Mod Pathol 2012, 25(3):347-369. 10.1038/modpathol.2011.215, 22282308.
3. Bonanno L, Schiavon M, Nardo G, Bertorelle R, Bonaldi L, Galligioni A, Indraccolo S, Pasello G, Rea F, Favaretto A. Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma. Anticancer Res 2010, 30(12):5121-5128.
4. Casorzo L, Corigliano M, Ferrero P, Venesio T, Risio M. Evaluation of 7q31 region improves the accuracy of EGFR FISH assay in non small cell lung cancer. Diagn Pathol 2009, 4:36. 10.1186/1746-1596-4-36, 2781797, 19889201.
5. da Cunha SG, Shepherd FA, Tsao MS. EGFR mutations and lung cancer. Annu Rev Pathol 2011, 6:49-69. 10.1146/annurev-pathol-011110-130206, 20887192.
6. Pirker R, Herth FJ, Kerr KM, Filipits M, Taron M, Gandara D, Hirsch FR, Grunenwald D, Popper H, Smit E. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol 2010, 5(10):1706-1713. 10.1097/JTO.0b013e3181f1c8de, 20871269.
7. Yu J, Kane S, Wu J, Benedettini E, Li D, Reeves C, Innocenti G, Wetzel R, Crosby K, Becker A. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res 2009, 15(9):3023-3028. 10.1158/1078-0432.CCR-08-2739, 19366827.
8. Simonetti S, Molina MA, Queralt C, de Aguirre I, Mayo C, Bertran-Alamillo J, Sanchez JJ, Gonzalez-Larriba JL, Jimenez U, Isla D. Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer. J Transl Med 2010, 8:135. 10.1186/1479-5876-8-135, 3016260, 21167064.
9. Kato Y, Peled N, Wynes MW, Yoshida K, Pardo M, Mascaux C, Ohira T, Tsuboi M, Matsubayashi J, Nagao T. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations. J Thorac Oncol 2010, 5(10):1551-1558. 10.1097/JTO.0b013e3181e9da60, 2946481, 20697298.
10. Kitamura A, Hosoda W, Sasaki E, Mitsudomi T, Yatabe Y. Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer. Clin Cancer Res 2010, 16(13):3349-3355. 10.1158/1078-0432.CCR-10-0129, 20570926.
11. Brevet M, Arcila M, Ladanyi M. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn 2010, 12(2):169-176. 10.2353/jmoldx.2010.090140, 2871723, 20093391.
12. Wu SG, Chang YL, Lin JW, Wu CT, Chen HY, Tsai MF, Lee YC, Yu CJ, Shih JY. Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction. PLoS One 2011, 6(8):e23303. 10.1371/journal.pone.0023303, 3153495, 21858063.
13. Kozu Y, Tsuta K, Kohno T, Sekine I, Yoshida A, Watanabe S, Tamura T, Yokota J, Suzuki K, Asamura H. The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma. Lung Cancer 2011, 73(1):45-50. 10.1016/j.lungcan.2010.11.003, 21129809.
14. Hofman P, Ilie M, Hofman V, Roux S, Valent A, Bernheim A, Alifano M, Leroy-Ladurie F, Vaylet F, Rouquette I. Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma. Ann Oncol 2012, 23(7):1738-1743. 10.1093/annonc/mdr535, 22100693.
15. Kawahara A, Yamamoto C, Nakashima K, Azuma K, Hattori S, Kashihara M, Aizawa H, Basaki Y, Kuwano M, Kage M. Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis. Clin Cancer Res 2010, 16(12):3163-3170. 10.1158/1078-0432.CCR-09-3239, 20423982.
16. Lamy PJ, Jacot W. Worldwide variations in EGFR somatic mutations: a challenge for personalized medicine. Diagn Pathol 2012, 7:13. 10.1186/1746-1596-7-13, 3277478, 22293080.
17. Otto C, Csanadi A, Fisch P, Werner M, Kayser G. Molecular modeling and description of a newly characterized activating mutation of the EGFR gene in non-small cell lung cancer. Diagn Pathol 2012, 7:146. 10.1186/1746-1596-7-146, 3523061, 23088930.
18. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361(10):947-957. 10.1056/NEJMoa0810699, 19692680.
19. Savic SGB, Rufle A, Bihl M, Barascud A, Herzog M, Tapia C, Terracciano L, Feichter G, Bubendorf L. EGFR-gene analysis on cytological specimens of non-small-cell lung cancers. Diagn Pathol 2007, 2(Suppl 1):1. 10.1186/1746-1596-2-S1-S1, 1779261, 17212821.